Literature DB >> 7815561

Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts.

J F Cavender1, A Conn, M Epler, H Lacko, M J Tevethia.   

Abstract

The simian virus 40 large T antigen immortalizes growing primary cells in culture. In addition, this viral oncoprotein cooperates with an activated ras protein to produce dense foci on monolayers of rat embryo fibroblasts (REF). The relationship between independent immortalization and cooperative transformation with ras has not been defined. Previously, two regions of T antigen were shown to contain immortalization activities. An N-terminal fragment consisting of amino acids 1 to 147 immortalizes rodent cells (L. Sompayrac and K. J. Danna, Virology 181:412-415, 1991). Loss-of-function analysis indicated that immortalization depended on integrity of the T-antigen segments containing amino acids 351 to 450 and 533 to 626 (T. D. Kierstead and M. J. Tevethia, J. Virol. 67:1817-1829, 1993). The experiments described here were directed toward determining whether these same T-antigen regions were sufficient for cooperation with ras. Initially, constructs that produce T antigens containing amino acids 176 to 708 (T176-708) or 1 to 147 were tested in a ras cooperation assay. Both polypeptides cooperated with ras to produce dense foci on monolayers of primary REF. These results showed that T antigen contains two separate ras cooperation activities. In order to determine the N-terminal limit of the ras cooperation activity contained within the T176-708 polypeptide, a series of constructs designed to produce fusion proteins containing T-antigen segments beginning at residues 251, 301, 337, 351, 371, 401, 451, 501, 551, 601, and 651 was generated. Each of these constructs was tested for the capacity to cooperate with ras to produce dense foci on REF monolayers. The results indicated that a polypeptide containing T-antigen amino acids 251 to 708 (T251-708) was sufficient to cooperate with ras, whereas the more extensively truncated products were not. The abilities of the N-terminally truncated T antigens to bind p53 were examined in p53-deficient cells infected with a recombinant vaccinia virus expressing a phenotypically wild-type mouse p53. The results showed that polypeptides containing T-antigen amino acids 251 to 708, 301 to 708, 337 to 708, or 351 to 708 retained p53-binding capacity. The introduction into the T251-708 polypeptide of deletions that either prevented p53 binding (dl434-444) or did not prevent p53 binding (dl400) abrogated ras cooperation. These results indicated that although p53 binding may be necessary for ras cooperation, an additional, as-yet-undefined activity contained within the T251-708 polypeptide is needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815561      PMCID: PMC188661     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  The large tumor antigen of simian virus 40 encodes at least two distinct transforming functions.

Authors:  A Srinivasan; K W Peden; J M Pipas
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

2.  SV40 T antigen abrogates p53-mediated transcriptional activity.

Authors:  D Jiang; A Srinivasan; G Lozano; P D Robbins
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

3.  Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformation.

Authors:  S J van den Heuvel; T van Laar; I The; A J van der Eb
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

4.  The amino-terminal functions of the simian virus 40 large T antigen are required to overcome wild-type p53-mediated growth arrest of cells.

Authors:  R S Quartin; C N Cole; J M Pipas; A J Levine
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  The kinetics of simian virus 40-induced progression of quiescent cells into S phase depend on four independent functions of large T antigen.

Authors:  A Dickmanns; A Zeitvogel; F Simmersbach; R Weber; A K Arthur; S Dehde; A G Wildeman; E Fanning
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms.

Authors:  B Mosley; M P Beckmann; C J March; R L Idzerda; S D Gimpel; T VandenBos; D Friend; A Alpert; D Anderson; J Jackson
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

7.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

8.  Stabilization of the tumor suppressor p53 during cellular transformation by simian virus 40: influence of viral and cellular factors and biological consequences.

Authors:  F Tiemann; W Deppert
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53.

Authors:  D H Mack; J Vartikar; J M Pipas; L A Laimins
Journal:  Nature       Date:  1993-05-20       Impact factor: 49.962

10.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  24 in total

1.  Regions and activities of simian virus 40 T antigen that cooperate with an activated ras oncogene in transforming primary rat embryo fibroblasts.

Authors:  Tina M Beachy; Sara L Cole; Jane F Cavender; Mary J Tevethia
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  A simian virus 40 large T-antigen segment containing amino acids 1 to 127 and expressed under the control of the rat elastase-1 promoter produces pancreatic acinar carcinomas in transgenic mice.

Authors:  M J Tevethia; R H Bonneau; J W Griffith; L Mylin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Transcriptional control of SV40 T-antigen expression allows a complete reversion of immortalization.

Authors:  Tobias May; Hansjörg Hauser; Dagmar Wirth
Journal:  Nucleic Acids Res       Date:  2004-10-14       Impact factor: 16.971

4.  Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse.

Authors:  Erin M Goodwin; Qing Zhong; Catherine S Abendroth; Lindsay K Ward-Kavanagh; Todd D Schell; Timothy K Cooper
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

5.  Differential interaction of temperature-sensitive simian virus 40 T antigens with tumor suppressors pRb and p53.

Authors:  S Ray; M E Anderson; P Tegtmeyer
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  p300 family members associate with the carboxyl terminus of simian virus 40 large tumor antigen.

Authors:  N L Lill; M J Tevethia; R Eckner; D M Livingston; N Modjtahedi
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Adding an Rb-binding site to an N-terminally truncated simian virus 40 T antigen restores growth to high cell density, and the T common region in trans provides anchorage-independent growth and rapid growth in low serum concentrations.

Authors:  M J Tevethia; H A Lacko; T D Kierstead; D L Thompson
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

8.  pRB-dependent, J domain-independent function of simian virus 40 large T antigen in override of p53 growth suppression.

Authors:  O Gjoerup; H Chao; J A DeCaprio; T M Roberts
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

9.  Transactivation of E2F-regulated genes by polyomavirus large T antigen: evidence for a two-step mechanism.

Authors:  Maria Nemethova; Michael Smutny; Erhard Wintersberger
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  Transactivation of a ribosomal gene by simian virus 40 large-T antigen requires at least three activities of the protein.

Authors:  J F Cavender; C Mummert; M J Tevethia
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.